

To expedite processing, please send the	following information with prescription
Referral Form	List of Tried and Failed Meds (Including other Biologics)
Demographic Sheet	Prescription Insurance Card (Front & Back)
Most Recent Clinical Notes	
Bio-Coordinator or Primary	y Point of Contact at Clinic:
Name:	
Email:	
Direct Phone Line:	
Call (antiqual but professed):	

**Genefic Specialty Pharmacy** 2577 Mall Road, Suite B Florence, AL, 35630

> Phone: (833) 928-7660 Fax: (833) 928-7661 Website: GeneficRx.com

				Pres	criber:						NPI:		
Hepatitis C Enrollment Form		Supervising Physician:							NPI:				
		Address:							Tax ID:				
				Phon	ie:				Fax:				
			Conta	act:									
PATIENT INFORMATION													
					DOB:				:	SS#:			
Street: City:		City:							ZIP:	ZIP:			
Phone:	Phone: Alt. Phone:						On and the Other			Wt.:	Wt.: Ht.:		
PRESCRIPTION													
□ New □ Refill	Ship by: /	1	_ Ship	o to:	□ Patient's H				Other	:			
Drug Epclusa®	Strength				00 :11 :11		ections & Q					Refills	
(sofosbuvir/velpatasvir)	□400/100 mg Tablet □Take one table				QD with or with	out food	d (Quantity:	28)					
Harvoni® (ledipasvir/sofosbuvir)	□90/400 mg Ta	ablet	☐ Take one tab	let PO	QD with or with	out foo	d (Quantity	: 28)					
Mavyret™	□ 100/40 mg Tablet □ Take three ta				O QD with food	d (Quan	ntity: 84)						
Sovaldi <sup>®</sup>	□ 400 mg Tablet □ Take one tablet				QD with or with	out foo	d (Quantity	: 28)					
Viekira Pak®	☐ 12.5/75/50 mg Tablet ☐ Take two pink meal (Quantity: 5					ning) an	nd one beig	e tablet PC	BID (mo	orning ar	nd evening) with a		
Vosevi®	□400/100/100 mg Tablet □Take one tablet PO QD with food (Quantity: 28)												
Zepatier <sup>®</sup>	□50/100 mg Ta	100 mg Tablet Take one tablet PO QD with or without food (Quantity: 28)											
	Directions & Qua	ntity	F	RIBAV	IRIN PRODUC	TS		1				I	
Takemg QAM,mg QPM (Quantity:)				☐ Ribavirin Tablet			Ribavirin Capsule						
MEDICAL INFORMATION  ***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES & LAB WORK REGARDING THERAPY***													
Diagnosis: □ B18.2 Chronic Hepatitis C Virus (HCV) Date of Diagnosis: _ / _ / Treatment Naïve? □ Yes □ No													
Genotype: 01 0 2 0 3 0 4 0 5 0 6 Subtype: 0 A 0 B 0 A/B 0 N/A Baseline viral load:													
Cirrhosis: ☐ Yes ☐ No (if yes, is it: ☐ compensated ☐ decompensated)  Co-infection status: ☐ HIV ☐ HBV ☐ N/A													
Degree of liver fibrosis:         □ F1         □ F2         □ F3         □ F4         Polymorphism(s):         □ NS5A         □ L28B         □ Q80K         □ N/A													
			Date(s) of treatment:							Treatment Response: e ☐ Null ☐ Partial ☐ Relapsed			
										□ Null □ Partial □ R			
										□ <sub>Null</sub> □ <sub>Partial</sub> □ <sub>R</sub>			
Additional Clinical Information:  Expected Duration of Therapy:   8 weeks  12 weeks  16 weeks  24 weeks								24 weeks					
Additional Clinical Inion	mauon.												
To Prescriber: By signing			SIGNATURE R							al and pro	scription insurance company	ies and	
copay assistance foundation	this form and utilizing our serv s.				e as your prior auth	orization o	designated ag			al and pre	scription insurance compani	ies, and	
copay assistance foundation PRODUCT SUBSTITU	this form and utilizing our serv s.	ices, you are a	also authorizing Genefi		e as your prior auth	orization o						ies, and	
copay assistance foundation	this form and utilizing our serv s.	ices, you are a		c to serve	e as your prior auth  DISPEN  X	orization o	designated ag				scription insurance compani	ies, and	